Posaconazole for paediatric patients: Status of development and future perspectives

Mycoses

Volumn 51, Issue SUPPL. 2, 2008, Pages 5-11

  Groll, Andreas H ^a   Lehrnbecher, Thomas ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antifungal agents; Children; Mycoses; Posaconazole; Prevention; Treatment

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS TERREUS; CANDIDA GLABRATA; CANDIDA KRUSEI; CHROMOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FUSARIOSIS; FUSARIUM; HEADACHE; HUMAN; LIVER FUNCTION TEST; MUCORMYCOSIS; MYCOSIS; NAUSEA; OROPHARYNX CANDIDIASIS; PATIENT; PATIENT COMPLIANCE; PEDIATRIC PATIENT; PRIORITY JOURNAL; RASH; REVIEW; SALVAGE THERAPY; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTIFUNGAL; CHILD; CHILD, PRESCHOOL; HUMANS; MYCOSES; TRIAZOLES;

EID: 47949092652     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01569.x     Document Type: Review

References (32)

1. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003 17 : 159 91.
2. Bennett F, Saksena AK, Lovey RG et al. Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg Med Chem Lett 2006 16 : 186 90.
3. Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005 3 : 467 87.
4. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006 50 : 2009 15.
5. Groll AH, Walsh TJ. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 2006 49 (Suppl. 1 7 16.
6. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003 47 : 2788 95.
7. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004 48 : 3543 51.
8. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 21 : 645 53.
9. Sansone A, Courtney R, Krishna G. Evaluation of the drug interaction potential of posaconazole: sumary of 7 clinical pharmacology studies. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC : American Society for Microbiology, 2003 (Abstr. P-1107).
10. Pedicone L, Ullmann AJ, Graybill J et al. Comparison of posaconazole adverse event profiles in healthy volunteers and patients with invasive fungal infections. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC : American Society for Microbiology, 2004 (Abstr. P-1106).
11. Raad II, Graybill JR, Bustamante AB et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006 42 : 1726 34.
12. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 47.
13. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 59.
14. Vasquez JA, Northland R, Miller S. Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients. Abstracts of the 40st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC : American Society for Microbiology, 2000 (Abstr. 1107).
15. Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007 44 : 607 14.
16. Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006 42 : 1179 86.
17. Raad I, Chapman S, Bradsher R, Morrison V, Goldmann M, Graybill J. Posaconazole salvage therapy for invasive fungal infections. Abstracts of the 44st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC : American Society for Microbiology, 2004 (Abstr. M-669).
18. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
19. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006 42 : e61 5.
20. Sansone-Parsons A, Krishna G, Simon J et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007 51 : 495 502.
21. Courtney R, Sansone A, Smith W et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005 45 : 185 92.
22. Courtney R. Pharmacokinetics of posaconazole in patients with hepatic insufficiency. Abstracts of the Annual Meeting of the American Academy for Pharmacological Sciences (AAPS), Washington, DC, 2000 (Abstr. 3495).
23. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007 51 : 812 8.
24. Simmons JH, Zeitler PS, Fenton LZ, Abzug MJ, Fiallo-Scharer RV, Klingensmithn GJ. Rhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature. Pediatr Diabetes 2005 6 : 234 8.
25. Notheis G, Tarani L, Costantino F et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006 49 (Suppl. 1 37 41.
26. Gelston CD, Durairaj VD, Simoes EA. Rhino-orbital mucormycosis causing cavernous sinus and internal carotid thrombosis treated with posaconazole. Arch Ophthalmol 2007 125 : 848 9.
27. De Decker K, Van Poucke S, Wojciechowski M et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr Crit Care Med 2006 7 : 482 5.
28. Sorensen J, Becker M, Porto L et al. Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses 2006 49 (Suppl. 1 31 6.
29. Chan Y, Goldwater P, Saxon B. Successful treatment of cutaneous and subcutaneous zygomycosis in an immunosuppressed patient with aplastic anaemia. J Paediatr Child Health 2007 43 : 87 9.
30. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005 40 : 1684 8.
31. Wynne SM, Kwon-Chung KJ, Shea YR et al. Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease. J Allergy Clin Immunol 2004 114 : 1418 24.
32. Groll AH. Drug therapy in paediatric patients. Lancet 2001 357 : 719.